PC
AVDL

Polar Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Polar Capital’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$15M Hold
2,978,915
– – 0.11% 155
2020
Q2 		$24.1M Buy
+2,978,915
New +$26.3M 0.21% 118

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Polar Capital's AVDL Position: Q3 2020 in Review

Polar Capital held its Avadel Pharmaceuticals (AVDL) position steady in Q3 2020 at 2,978,915 shares worth $15M. The position accounts for 0.11% of the portfolio, ranked #155.

Polar Capital first reported a position in AVDL in Q2 2020 and has held it in 2 quarters since. The position peaked at $24.1M in Q2 2020. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

  • Polar Capital held 2,978,915 shares of Avadel Pharmaceuticals worth $15M as of Q3 2020.
  • Polar Capital left its Avadel Pharmaceuticals share count unchanged in Q3 2020.
  • Avadel Pharmaceuticals made up 0.11% of Polar Capital's portfolio in Q3 2020, its #155 holding.
  • Polar Capital first reported a position in Avadel Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • Polar Capital's Avadel Pharmaceuticals position peaked at $24.1M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.